NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
AstraZeneca
Gilead Sciences
Eli Lilly and Company
M.D. Anderson Cancer Center
Fudan University
National Institutes of Health Clinical Center (CC)